SI-BONE Inc

SIBN

Market cap $640M

NEWTOWN, Pa., Oct. 03, 2025 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating data privacy claims regarding an incident at SI-Bone, Inc. (“SI-Bone”).

SI-BONE, Inc. (NASDAQ:SIBN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:00 AM EDT Company Participants Laura Francis - CEO & Director Anshul Maheshwari - Chief Financial Officer Presentation Unknown Analyst All right. Good morning.

SANTA CLARA, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Tuesday, September 9, 2025, at 4:00 a.m. Pacific Time/ 07:00 a.m. Eastern Time.

Si-bone (SIBN 2.93%), a medical device innovator focused on minimally invasive surgery for joint dysfunction and pelvic conditions, released its second quarter 2025 results on August 4, 2025. The company reported GAAP revenue of $48.6 million and a GAAP net loss per share of $(0.14) for Q2 2025.

SI-BONE, Inc. (NASDAQ:SIBN ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Anshul Maheshwari - Chief Financial Officer Laura A. Francis - CEO & Director Saqib Iqbal - Director of FP&A and Investor Relations Conference Call Participants Caitlin Cronin - Canaccord Genuity Corp., Research Division Craig William Bijou - BofA Securities, Research Division David Joshua Saxon - Needham & Company, LLC, Research Division David Louis Turkaly - Citizens JMP Securities, LLC, Research Division Felipe Raul Lamar - Truist Securities, Inc., Research Division Junwoo Park - Cantor Fitzgerald & Co., Research Division Matthew Oliver O'Brien - Piper Sandler & Co., Research Division Xuyang Li - Jefferies LLC, Research Division Operator Good afternoon, and welcome to SI-BONE Second Quarter 2025 Earnings Conference Call.

Si-Bone (SIBN) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.22 per share a year ago.

Achieved ~22% worldwide revenue growth, positive Adjusted EBITDA and cash flow breakeven Achieved ~22% worldwide revenue growth, positive Adjusted EBITDA and cash flow breakeven

SANTA CLARA, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, August 12, 2025, at 12:00 p.m. Pacific Time/03:00 p.m. Eastern Time.

SANTA CLARA, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the second quarter of 2025 after market close on Monday, August 4, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Si-Bone (SIBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).